Journal of Clinical Research

2020 Conference Announcement Open Access

2020 Market Report of Clinical Research & Clinical Trails Conference

Donato Bonifazi

Department of Pharmaceutical Research Management SRL, Lodi, Italy
E-mail: ceo@cvbf.net

On behalf of Organizing Committee, We cordially invite you as a speaker at the 10th International Conference on Clinical Research and Clinical Trials which is scheduled on March 18-19, 2020 in Amsterdam, Netherlands.

Euro Clinical Trials 2020 is a global overview with the Theme: **"Revolutionary Advancements in Clinical Research and Clinical Trials".**

This event gathering people from all over the globe and covers different sessions, in which the exchanges incorporate the different tracks- Clinical Trails and advancement, Clinical Data Management, Ethics in Clinical Trials and research, Patient-Centric Clinical Trials, Bioinformatics in Clinical Research, Innovations in Clinical Trials, Future of Clinical Trials, Clinical and Medical Case Reports.

Global Market value of Clinical Trials

The global clinical trials market size is expected to reach $68.9 billion by 2026. It is projected to expand at a CAGR of 5.7% during the forecast period. Key drivers impacting the market growth are globalization of clinical trials, development of new treatments such as personalized medicine, augmenting evolution in technology, and rising demand for CROs to conduct clinical trials. Globalization has led to increase in investment in new product development in emerging countries thereby, positively impacting the market. The availability of the vast array of services from drug discovery to post-marketing surveillance has further simplified the life for mid-size and small-scale pharmaceutical and biotechnological organizations by providing them the option to outsource what they think is beyond their core expertise.



As rare diseases have considerably low prevalence rate, as compared to other diseases, drug manufacturers were previously not interested in developing drugs for rare diseases, due to the low earnings in this category. However, the situation has changed currently, as companies are increasingly focusing on cures for rare diseases, specifically in developed countries. In fact, the percentage share of orphan drugs approved by FDA increased from 33% in 2013 to 47% in 2015. Favorable government policies contributed majorly to this drive. The United States was the first to implement such policies, starting with the Orphan Drug Act (ODA) of 1983, encouraging pharmaceutical companies to develop drugs for diseases that had less market demand. Tax credits were offered for R&D costs and tax incentives were offered for clinical trials.

The Conference Series of Clinical Research Conferences embrace research scholars, Academic professors who

endeavour to disseminate their research experience to escalate the forthcoming research ideas. This includes International Conferences, Workshops, Symposia, Trade Shows, Exhibitions and Science Congresses in all the major logical orders, including Clinical, Medical and pharmaceutical, Chemistry, Engineering, Technology, Business Management and Life Sciences crosswise over America, Europe, The Middle East and Asia Pacific.

Contact:

Katherine James

Program Manager

Euro Clinical Trials 2020

clinicaltrials@europemeet.com